BSI-060T is under clinical development by Pyxis Oncology and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BSI-060T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BSI-060T is under development for the treatment of solid tumors including ovarian cancer, colorectal cancer, melanoma, endometrial cancer, thyroid cancer, non-small cell lung cancer, squamous cell carcinoma, head and neck cancer squamous cell carcinoma, merkel cell carcinoma, breast cancer, bladder cancer, cholangiocarcinoma and kidney cancer. It is administered by intravenous route. The therapeutic candidate is a monoclonal antibody developed based on H3 (high-throughput, high-content, high-efficiency) antibody platform and SynAb technology. It acts by targeting SIGLEC15.
Pyxis Oncology overview
Pyxis Oncology is an immuno-oncology company that develops anti-body drug conjugates (ADC) and immunotherapies for cancer. It is investigating PYX-201 to treat solid tumors; PYX-202 program to treat soft tissue sarcoma; and PYX-203 drug against myelodysplastic syndromes (MDS) and acute myeloid leukemia. The company utilizes its proprietary flexible antibody conjugation technology (FACT) platform to develop ADCs. Pyxis Oncology’s platform technology analyses promising tumor targets and acquires highly specific antibodies to these tumor targets. It carries out research and development with pharmaceutical and biotech companies to develop innovative medicines. Pyxis Oncology is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of BSI-060T’s drug-specific PTSR and LoA scores, buy the report here.